A pair of Korean companies have teamed up to buy stem cell manufacturing facilities and other assets of a failed U.S. biotech to establish a foothold in the U.S.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,